Table 3.

Hazard ratios for site specific infections comparing matched users and non-users of tumour necrosis factor-α (TNF-α) inhibitors within a 365 days risk period

Infection sites	Users of TNF-α inhibitors			Non-users of TNF-α inhibitors		Hazard ratio (95% CI)
	No of patients	No of events		No of patients	No of events
Gastrointestinal	1543	28		1543	24	1.01 (0.55 to 1.86)
Respiratory tract	1543	30		1543	28	0.75 (0.42 to 1.34)
Skin and soft tissue	1543	26		1543	13	2.51 (1.23 to 5.12)
Urological or gynaecological	1543	9		1543	4	2.31 (0.64 to 8.29)
Sepsis	1543	6		1543	4	2.45 (0.65 to 9.19)
Other	1543	8		1543	5	1.24 (0.36 to 4.30)